Publications
Selected publications
- Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism (Journal article - 2014)
- The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer (Journal article - 2013)
- Loss of MTBP Expression Is Associated With Reduced Survival in a Biomarker-Defined Subset of Patients With Squamous Cell Carcinoma of the Head and Neck (Journal article - 2011)
- The nucleolus directly regulates p53 export and degradation (Journal article - 2011)
- MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility (Journal article - 2011)
2025
Urinary metabolite model to predict the dying process in lung cancer patients.
Coyle, S., Chapman, E., Hughes, D. M., Baker, J., Slater, R., Davison, A. S., . . . Probert, C. (2025). Urinary metabolite model to predict the dying process in lung cancer patients.. Communications medicine, 5(1), 49. doi:10.1038/s43856-025-00764-3
2023
GC-MS Techniques Investigating Potential Biomarkers of Dying in the Last Weeks with Lung Cancer
Chapman, E. A., Baker, J., Aggarwal, P., Hughes, D. M., Nwosu, A. C., Boyd, M. T., . . . Coyle, S. (2023). GC-MS Techniques Investigating Potential Biomarkers of Dying in the Last Weeks with Lung Cancer. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(2). doi:10.3390/ijms24021591
2021
Metabolic Plasticity and Combinatorial Radiosensitisation Strategies in Human Papillomavirus-Positive Squamous Cell Carcinoma of the Head and Neck Cell Lines
Wilkie, M. D., Anaam, E. A., Lau, A. S., Rubbi, C. P., Vlatkovic, N., Jones, T. M., & Boyd, M. T. (2021). Metabolic Plasticity and Combinatorial Radiosensitisation Strategies in Human Papillomavirus-Positive Squamous Cell Carcinoma of the Head and Neck Cell Lines. CANCERS, 13(19). doi:10.3390/cancers13194836
Metabolism and Anti-Metabolic Therapeutic Strategies in Human Papillomavirus-Positive Squamous Cell Carcinoma of the Head and Neck
Wilkie, M. D., Lau, A. S., Vlatkovic, N., Jones, T. M., & Boyd, M. T. (2021). Metabolism and Anti-Metabolic Therapeutic Strategies in Human Papillomavirus-Positive Squamous Cell Carcinoma of the Head and Neck. In ORAL ONCOLOGY Vol. 118. Retrieved from https://www.webofscience.com/
2020
Optimisation of Urine Sample Preparation for Headspace-Solid Phase Microextraction Gas Chromatography-Mass Spectrometry: Altering Sample pH, Sulphuric Acid Concentration and Phase Ratio
Aggarwal, P., Baker, J., Boyd, M. T., Coyle, S., Probert, C., & Chapman, E. A. (2020). Optimisation of Urine Sample Preparation for Headspace-Solid Phase Microextraction Gas Chromatography-Mass Spectrometry: Altering Sample pH, Sulphuric Acid Concentration and Phase Ratio. METABOLITES, 10(12). doi:10.3390/metabo10120482
TP53 mutations in head and neck cancer cells determine the Warburg phenotypic switch creating metabolic vulnerabilities and therapeutic opportunities for stratified therapies
Wilkie, M. D., Anaam, E. A., Lau, A. S., Rubbi, C. P., Jones, T. M., Boyd, M. T., & Vlatković, N. (2020). TP53 mutations in head and neck cancer cells determine the Warburg phenotypic switch creating metabolic vulnerabilities and therapeutic opportunities for stratified therapies. Cancer Letters, 478, 107-121. doi:10.1016/j.canlet.2020.02.032
2018
Molecular pathogenesis of proliferative verrucous leukoplakia: a systematic review
Okoturo, E. M., Risk, J. M., Schache, A. G., Shaw, R. J., & Boyd, M. T. (2018). Molecular pathogenesis of proliferative verrucous leukoplakia: a systematic review. BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 56(09), 780-785. doi:10.1016/j.bjoms.2018.08.010
Metabolic signature of squamous cell carcinoma of the head and neck: Consequences of <i>TP53</i> mutation and therapeutic perspectives
Wilkie, M. D., Lau, A. S., Vlatkovic, N., Jones, T. M., & Boyd, M. T. (2018). Metabolic signature of squamous cell carcinoma of the head and neck: Consequences of <i>TP53</i> mutation and therapeutic perspectives. ORAL ONCOLOGY, 83, 1-10. doi:10.1016/j.oraloncology.2018.05.018
2016
Relative expression of vascular endothelial growth factor isoforms in squamous cell carcinoma of the head and neck
Wilkie, M. D., Emmett, M. S., Santosh, S., Lightbody, K. A., Lane, S., Goodyear, P. W., . . . Jones, T. M. (2016). Relative expression of vascular endothelial growth factor isoforms in squamous cell carcinoma of the head and neck. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 38(5), 775-781. doi:10.1002/hed.23959
Modulating the p53/MDM2 axis to enhance outcomes of radiotherapy for head & neck cancer: tumour and normal tissue studies in vitro and in vivo
Wickham, M., Sansom, O., Boyd, M., Vlatkovic, N., Chalmers, A., & Jones, T. (2016). Modulating the p53/MDM2 axis to enhance outcomes of radiotherapy for head & neck cancer: tumour and normal tissue studies in vitro and in vivo. In BRITISH JOURNAL OF SURGERY Vol. 103 (pp. 40). Retrieved from https://www.webofscience.com/
2015
Tumour metabolism in squamous cell carcinoma of the head and neck: an in-vitro study of the consequences of <i>TP53</i> mutation and therapeutic implications
Wilkie, M., Lau, A., Vlatkovic, N., Jones, T., & Boyd, M. (2015). Tumour metabolism in squamous cell carcinoma of the head and neck: an in-vitro study of the consequences of <i>TP53</i> mutation and therapeutic implications. LANCET, 385, 101. doi:10.1016/S0140-6736(15)60416-0
Janus-faces of NME-oncoprotein interactions
Vlatkovic, N., Chang, S. -H., & Boyd, M. T. (2015). Janus-faces of NME-oncoprotein interactions. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 388(2), 175-187. doi:10.1007/s00210-014-1062-5
2014
Squamous cell carcinoma of the head and neck outside the oropharynx is rarely human papillomavirus related.
Upile, N., Shaw, R., Jones, T., Goodyear, P., Liloglou, L., Risk, J., . . . Schache, A. (2014). Squamous cell carcinoma of the head and neck outside the oropharynx is rarely human papillomavirus related.. The Laryngoscope, 124(12), 2739-2744. doi:10.1002/lary.24828
Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism
Polanski, R., Noon, A. P., Blaydes, J., Phillips, A., Rubbi, C. P., Parsons, K., . . . Boyd, M. T. (2014). Senescence induction in renal carcinoma cells by Nutlin-3: a potential therapeutic strategy based on MDM2 antagonism. Cancer Letters, 353(2), 211-219. doi:10.1016/j.canlet.2014.07.024
Nucleolar control of p53: a cellular Achilles' heel and a target for cancer therapy
Vlatkovic, N., Boyd, M. T., & Rubbi, C. P. (2014). Nucleolar control of p53: a cellular Achilles' heel and a target for cancer therapy. CELLULAR AND MOLECULAR LIFE SCIENCES, 71(5), 771-791. doi:10.1007/s00018-013-1361-x
2013
The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer
Thornton, M., Aslam, M. A., Tweedle, E. M., Ang, C., Campbell, F., Jackson, R., . . . Boyd, M. T. (2013). The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer. International Journal of Cancer, 133(6), 1408-1418. doi:10.1002/ijc.28137
The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer
Thornton, M., Aslam, M. A., Tweedle, E. M., Ang, C., Campbell, F., Jackson, R., . . . Boyd, M. T. (2013). The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer. INTERNATIONAL JOURNAL OF CANCER, 133(6), 1408-1418. doi:10.1002/ijc.28137
2012
Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy
Noon, A. P., Polanski, R., El-Fert, A. Y., Kalirai, H., Shawki, H., Campbell, F., . . . Boyd, M. T. (2012). Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy. BJU INTERNATIONAL, 109(8), 1250-1257. doi:10.1111/j.1464-410X.2011.10433.x
Analysis of the p53 pathway in clear cell renal cell carcinoma to identify novel drug combinations.
Boyd, M. T., Ahmed-Ebbiary, A., Polanski, R., Noon, A., Parsons, K., Rubbi, C. P., & Vlatkovic, N. (2012). Analysis of the p53 pathway in clear cell renal cell carcinoma to identify novel drug combinations.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30. doi:10.1200/jco.2012.30.5_suppl.460
2011
The nucleolus directly regulates p53 export and degradation
Boyd, M. T., Vlatkovic, N., & Rubbi, C. P. (2011). The nucleolus directly regulates p53 export and degradation. JOURNAL OF CELL BIOLOGY, 194(5), 689-703. doi:10.1083/jcb.201105143
MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility
Polanski, R., Maguire, M., Nield, P. C., Jenkins, R. E., Park, B. K., Krawczynska, K., . . . Boyd, M. T. (2011). MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility. CARCINOGENESIS, 32(8), 1133-1142. doi:10.1093/carcin/bgr070
Loss of MTBP Expression Is Associated With Reduced Survival in a Biomarker-Defined Subset of Patients With Squamous Cell Carcinoma of the Head and Neck
Vlatkovic, N., El-Fert, A., Devling, T., Ray-Sinha, A., Gore, D. M., Rubbi, C. P., . . . Boyd, M. T. (2011). Loss of MTBP Expression Is Associated With Reduced Survival in a Biomarker-Defined Subset of Patients With Squamous Cell Carcinoma of the Head and Neck. CANCER, 117(13), 2939-2950. doi:10.1002/cncr.25864
Loss of MTBP expression is associated with reduced survival in a biomarker-defined subset of patients with squamous cell carcinoma of the head and neck.
Vlatkovic, N., El-Fert, A., Devling, T., Ray-Sinha, A., Gore, D., Rubbi, C., . . . Boyd, M. (2011). Loss of MTBP expression is associated with reduced survival in a biomarker-defined subset of patients with squamous cell carcinoma of the head and neck.. Cancer, 117(13), 2939-2950.
Tissue-Specific Therapeutic Targeting of p53 in Cancer: One Size Does Not Fit All
Vlatkovic, N., Crawford, K., Rubbi, C. P., & Boyd, M. T. (2011). Tissue-Specific Therapeutic Targeting of p53 in Cancer: One Size Does Not Fit All. CURRENT PHARMACEUTICAL DESIGN, 17(6), 618-630. doi:10.2174/138161211795222568
MDM2 links poor survival and increased invasiveness in renal cell carcinoma
Boyd, M. T., Polanski, R., Noon, A., Warburton, H. E., Parsons, K., & Vlatkovic, N. (2011). MDM2 links poor survival and increased invasiveness in renal cell carcinoma. In BRITISH JOURNAL OF SURGERY Vol. 98 (pp. E1). Retrieved from https://www.webofscience.com/
Mdm2 interacts with nme2 (non-metastatic cells 2, protein) and suppresses the ability of nme2 to negatively regulate cell motility
Polanski, R., Maguire, M., Nield, P. C., Jenkins, R. E., Park, B. K., Krawczynska, K., . . . Boyd, M. T. (2011). Mdm2 interacts with nme2 (non-metastatic cells 2, protein) and suppresses the ability of nme2 to negatively regulate cell motility. Carcinogenesis, 32, 1133-1142.
2010
MDM2 promotes cell motility and invasiveness through a RING-finger independent mechanism
Polanski, R., Warburton, H. E., Ray-Sinha, A., Devling, T., Pakula, H., Rubbi, C. P., . . . Boyd, M. T. (2010). MDM2 promotes cell motility and invasiveness through a RING-finger independent mechanism. FEBS LETTERS, 584(22), 4695-4702. doi:10.1016/j.febslet.2010.10.049
Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
Arya, A. K., El-Fert, A., Devling, T., Eccles, R. M., Aslam, M. A., Rubbi, C. P., . . . Boyd, M. T. (2010). Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53. BRITISH JOURNAL OF CANCER, 103(2), 186-195. doi:10.1038/sj.bjc.6605739
Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
Arya, A. K., El-Fert, A., Devling, T., Eccles, R. M., Aslam, M. A., Rubbi, C. P., . . . Boyd, M. T. (2010). Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53. British Journal of Cancer, 103(2), 186-195. doi:10.1038/sj.bjc.6605739
p53 and MDM2 in Renal Cell Carcinoma Biomarkers for Disease Progression and Future Therapeutic Targets?
Noon, A. P., Vlatkovic, N., Polanski, R., Maguire, M., Shawki, H., Parsons, K., & Boyd, M. T. (2010). p53 and MDM2 in Renal Cell Carcinoma Biomarkers for Disease Progression and Future Therapeutic Targets?. CANCER, 116(4), 780-790. doi:10.1002/cncr.24841
A Systematic Review of p53 as a Prognostic Factor of Survival in Squamous Cell Carcinoma of the Four Main Anatomical Subsites of the Head and Neck
Tandon, S., Tudur-Smith, C., Riley, R. D., Boyd, M. T., & Jones, T. M. (2010). A Systematic Review of p53 as a Prognostic Factor of Survival in Squamous Cell Carcinoma of the Four Main Anatomical Subsites of the Head and Neck. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 19(2), 574-587. doi:10.1158/1055-9965.EPI-09-0981
2008
p53: a molecular marker for the detection of cancer.
Boyd, M. T., & Vlatkovic, N. (2008). p53: a molecular marker for the detection of cancer.. Expert opinion on medical diagnostics, 2(9), 1013-1024. doi:10.1517/17530059.2.9.1013
MDM2 regulates dihydrofolate reductase activity through monoubiquitination
Maguire, M., Nield, P. C., Devling, T., Jenkins, R. E., Park, B. K., Polanski, R., . . . Boyd, M. T. (2008). MDM2 regulates dihydrofolate reductase activity through monoubiquitination. CANCER RESEARCH, 68(9), 3232-3242. doi:10.1158/0008-5472.CAN-07-5271
<i>MDM2</i> polymorphisms and cancer risk in basal cell carcinoma
Boyd, M. T., & Vlatkovic, N. (2008). <i>MDM2</i> polymorphisms and cancer risk in basal cell carcinoma. BRITISH JOURNAL OF DERMATOLOGY, 158(3), 636. doi:10.1111/j.1365-2133.2007.08375.x
MDM2 polymorphisms and cancer risk in basal cell carcinoma
Boyd, M. T., & Vlatković, N. (n.d.). MDM2 polymorphisms and cancer risk in basal cell carcinoma. British Journal of Dermatology, 158(3), 636. doi:10.1111/j.1365-2133.2007.08375.x
Investigating the role of MDM2 in regulation of methylation
Maguire, M., Nield, P., Devling, T., Jenkins, R., Park, K., Polanski, R., . . . Boyd, M. (2008). Investigating the role of MDM2 in regulation of methylation. In NCRI Annual Meeting 2008 (pp. C75). Birmingham: NCRI.
MDM2 and p53 coexpression is associated with poor prognosis in renal cell carcinoma patients undergoing radical nephrectomy
Noon, A. P., Warburton, H. E., Shawki, H., Campbell, F., Parsons, K., & Boyd, M. T. (2008). MDM2 and p53 coexpression is associated with poor prognosis in renal cell carcinoma patients undergoing radical nephrectomy. BJU INTERNATIONAL, 101, 2. Retrieved from https://www.webofscience.com/
The effect of Nutlin-3 on laryngeal carcinoma cell lines with wild-type p53: a promising treatment strategy for laryngeal carcinoma.
Arya, A. K., El-Fert, A., Devlin, T., Jones, T. M., & Boyd, M. T. (2008). The effect of Nutlin-3 on laryngeal carcinoma cell lines with wild-type p53: a promising treatment strategy for laryngeal carcinoma.. clinical otolaryngology, 33, 299.
p53 in cancer diagnosis
Vlatkovic, N., & Boyd, M. T. (2008). p53 in cancer diagnosis. Unknown Journal, ?4000 words plus figs and refs.
2007
Suppressing mutant p53 - a novel gene therapy for colorectal cancer
Prior, C. R., Rooney, P. S., & Boyd, M. T. (2007). Suppressing mutant p53 - a novel gene therapy for colorectal cancer. ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 89(6), 647. Retrieved from https://www.webofscience.com/
2006
Models of cancer
Vlatkovic, N., & Boyd, M. T. (2006). Models of cancer. Drug Discovery Today: Disease Models, 3(2), 127-128. doi:10.1016/j.ddmod.2006.05.003
MTBP - the MDM2 binding protein and gene
Boyd, M., & Vlatkovic, N. (2006). MTBP - the MDM2 binding protein and gene.
Immunohistochemical expression of p53 and MDM2 within head and neck squamous cell carcinoma
Tandon, S., Beer, H., Jones, T. M., Birchall, M., Boyd, M., & Helliwell, T. R. (2006). Immunohistochemical expression of p53 and MDM2 within head and neck squamous cell carcinoma. Clinical Otolaryngology, 31(3), 247. doi:10.1111/j.1749-4486.2006.01236_8.x
2005
p53 regulation and function in renal cell carcinoma
Warburton, H. E., Brady, M., Vlatkovic, N., Linehan, W. M., Parsons, K., & Boyd, M. T. (2005). p53 regulation and function in renal cell carcinoma. CANCER RESEARCH, 65(15), 6498-6503. doi:10.1158/0008-5472.CAN-05-0017
MDM2 expression and p53 mutation in renal cell carcinoma.
Warburton, H. E., Parsons, K. F., Linehan, W. M., & Boyd, M. T. (2005). MDM2 expression and p53 mutation in renal cell carcinoma.. JOURNAL OF UROLOGY, 173(4), 104. doi:10.1016/S0022-5347(18)34632-9
Regulation of p53 and MDM2 activity by MTBP
Brady, M., Vlatkovic, N., & Boyd, M. T. (2005). Regulation of p53 and MDM2 activity by MTBP. MOLECULAR AND CELLULAR BIOLOGY, 25(2), 545-553. doi:10.1128/MCB.25.2.545-553.2005
2004
Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: Increased expression of matrix metalloproteinase-7 predicts poor survival
Jones, L. E., Humphreys, M. J., Campbell, F., Neoptolemos, J. P., & Boyd, M. T. (2004). Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: Increased expression of matrix metalloproteinase-7 predicts poor survival. CLINICAL CANCER RESEARCH, 10(8), 2832-2845. doi:10.1158/1078-0432.CCR-1157-03
Analysis of the role of the MDM2-P53 pathway in tumour evolution in renal cell carcinoma
Warburton, H. E., Parsons, K. F., Linehan, M. W., & Boyd, M. T. (2004). Analysis of the role of the MDM2-P53 pathway in tumour evolution in renal cell carcinoma. BRITISH JOURNAL OF CANCER, 91, S65. Retrieved from https://www.webofscience.com/
Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival
Jones, L. E., Humphreys, M. J., Campbell, F., Neoptolemos, J. P., & Boyd, M. T. (2004). Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. Clin Cancer Res, 10(8), 2832-2845. Retrieved from http://www.ncbi.nlm.nih.gov/
2003
Stimulation of human DNA polymerase ε by MDM2
Asahara, H., Li, Y., Fuss, J., Haines, D. S., Vlatkovic, N., Boyd, M. T., & Linn, S. (2003). Stimulation of human DNA polymerase ε by MDM2. NUCLEIC ACIDS RESEARCH, 31(9), 2451-2459. doi:10.1093/nar/gkg342
Stimulation of human DNA polymerase epsilon by MDM2
Asahara, H., Li, Y., Fuss, J., Haines, D. S., Vlatkovic, N., Boyd, M. T., & Linn, S. (2003). Stimulation of human DNA polymerase epsilon by MDM2. Nucleic Acids Res, 31(9), 2451-2459. Retrieved from http://www.ncbi.nlm.nih.gov/
2002
Expression of the chemokines MCP-1/JE and cytokine-induced neutrophil chemoattractant in early acute pancreatitis
Brady, M., Bhatia, M., Christmas, S., Boyd, M. T., Neoptolemos, J. P., & Slavin, J. (2002). Expression of the chemokines MCP-1/JE and cytokine-induced neutrophil chemoattractant in early acute pancreatitis. PANCREAS, 25(3), 260-269. doi:10.1097/00006676-200210000-00008
Expression of the chemokines MCP-1/JE and CINC in early acute pancreatitis.
Brady, M., Bhatia, M., Christmas, S., Boyd, M. T., Neoptolemos, J. P., & Slavin, J. (2002). Expression of the chemokines MCP-1/JE and CINC in early acute pancreatitis.. Pancreas.
2001
MDM2 blocks MTBP induced growth arrest by relocalising MTBP to the cytoplasm
Gore, D. M., Vlatkovic, N., Spiller, D., White, M., Dodson, A., Sutton, R., & Boyd, M. T. (2001). MDM2 blocks MTBP induced growth arrest by relocalising MTBP to the cytoplasm. BRITISH JOURNAL OF CANCER, 85, 81. Retrieved from https://www.webofscience.com/
2000
Assignment of the MDM2 binding protein gene (MTBP) to human chromosome band 8q24 by in situ hybridization
Boyd, M. T., Zimonjic, D. B., Popescu, N. C., Athwal, R., & Haines, D. S. (2000). Assignment of the MDM2 binding protein gene (MTBP) to human chromosome band 8q24 by in situ hybridization. CYTOGENETICS AND CELL GENETICS, 90(1-2), 64-65. doi:10.1159/000015663
A novel cellular protein (MTBP) binds to MDM2 and induces a G<sub>1</sub> arrest that is suppressed by MDM2
Boyd, M. T., Vlatkovic, N., & Haines, D. S. (2000). A novel cellular protein (MTBP) binds to MDM2 and induces a G<sub>1</sub> arrest that is suppressed by MDM2. JOURNAL OF BIOLOGICAL CHEMISTRY, 275(41), 31883-31890. doi:10.1074/jbc.M004252200
MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase ε
Vlatkovic, N., Guerrera, S., Li, Y., Linn, S., Haines, D. S., & Boyd, M. T. (2000). MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase ε. NUCLEIC ACIDS RESEARCH, 28(18), 3581-3586. doi:10.1093/nar/28.18.3581
Fas-mediated apoptosis eliminates B cells that acquire self-reactivity during the germinal center response to NP
Hoch, S., Boyd, M., Malone, B., Gonye, G., Schwaber, J., & Schwaber, J. (2000). Fas-mediated apoptosis eliminates B cells that acquire self-reactivity during the germinal center response to NP. CELLULAR IMMUNOLOGY, 203(2), 103-110. doi:10.1006/cimm.2000.1681
A novel MDM2 binding protein (MTBP) induces a G1 arrest that is suppressed by MDM2
Vlatkovic, N., Magee, C., & Boyd, M. T. (2000). A novel MDM2 binding protein (MTBP) induces a G1 arrest that is suppressed by MDM2. British Journal of Cancer, 83, P125.
A novel MDM2 binding protein (MTBP) induces a G1 arrest that is suppressed by MDM2
Vlatkovic, N., Magee, C., & Boyd, M. T. (2000). A novel MDM2 binding protein (MTBP) induces a G1 arrest that is suppressed by MDM2. In BRITISH JOURNAL OF CANCER Vol. 83 (pp. 60). Retrieved from https://www.webofscience.com/
BTK mutations in patients with X-linked agammaglobulinemia: lack of correlation between presence of peripheral B lymphocytes and specific mutations.
Tao, L., Boyd, M., Gonye, G., Malone, B., & Schwaber, J. (2000). BTK mutations in patients with X-linked agammaglobulinemia: lack of correlation between presence of peripheral B lymphocytes and specific mutations.. Human mutation, 16(6), 528-529. doi:3.0.co;2-t">10.1002/1098-1004(200012)16:6<528::aid-humu12>3.0.co;2-t
Fas-mediated apoptosis eliminates B cells that acquire self-reactivity during the germinal centre response to NP.
Hoch, S., Boyd, M., Malone, B., Gonye, G., Schwaber, J., & Schwaber, J. (2000). Fas-mediated apoptosis eliminates B cells that acquire self-reactivity during the germinal centre response to NP.. In ARTHRITIS AND RHEUMATISM Vol. 43 (pp. S238). Retrieved from https://www.webofscience.com/
1997
Evidence for copurification of HERV-K-related transcripts and a reverse transcriptase activity in human platelets from patients with essential thrombocythemia
Boyd, M. T., Foley, B., & Brodsky, I. (1997). Evidence for copurification of HERV-K-related transcripts and a reverse transcriptase activity in human platelets from patients with essential thrombocythemia. BLOOD, 90(10), 4022-4030. doi:10.1182/blood.V90.10.4022
A novel exogenous retrovirus sequence identified in humans
Griffiths, D. J., Venables, P. J. W., Weiss, R. A., & Boyd, M. T. (1997). A novel exogenous retrovirus sequence identified in humans. JOURNAL OF VIROLOGY, 71(4), 2866-2872. doi:10.1128/JVI.71.4.2866-2872.1997
1996
Endogenous D-type (HERV-K) related sequences are packaged into retroviral particles in the placenta and possess open reading frames for reverse transcriptase
Simpson, G. R., Patience, C., Lower, R., Tonjes, R. R., Moore, H. D. M., Weiss, R. A., & Boyd, M. T. (1996). Endogenous D-type (HERV-K) related sequences are packaged into retroviral particles in the placenta and possess open reading frames for reverse transcriptase. VIROLOGY, 222(2), 451-456. doi:10.1006/viro.1996.0443
Mutations in the vpu, env, and nef genes of a syncytium-inducing variant of HIV type 1 JR-CSF that infects a range of T cell lines
Klasse, P. J., Boyd, M. T., Weiss, R. A., & Schulz, T. F. (1996). Mutations in the vpu, env, and nef genes of a syncytium-inducing variant of HIV type 1 JR-CSF that infects a range of T cell lines. AIDS RESEARCH AND HUMAN RETROVIRUSES, 12(4), 347-350. doi:10.1089/aid.1996.12.347
Expression of the estrogen receptor gene in developing and adult human breast
Boyd, M. T., Hildebrandt, R. H., & Bartow, S. A. (1996). Expression of the estrogen receptor gene in developing and adult human breast. BREAST CANCER RESEARCH AND TREATMENT, 37(3), 243-251. doi:10.1007/BF01806506
Human endogenous retrovirus expression and reverse transcriptase activity in the T4D mammary carcinoma cell line
Patience, C., Simpson, G. R., Colletta, A. A., Welch, H. M., Weiss, R. A., & Boyd, M. T. (1996). Human endogenous retrovirus expression and reverse transcriptase activity in the T4D mammary carcinoma cell line. JOURNAL OF VIROLOGY, 70(4), 2654-2657. doi:10.1128/JVI.70.4.2654-2657.1996
Human endogenous retrovirus-K encodes platelet retrovirus-like particles.
Foley, B., Boyd, M., & Brodsky, I. (1996). Human endogenous retrovirus-K encodes platelet retrovirus-like particles.. In BLOOD Vol. 88 (pp. 3547). Retrieved from https://www.webofscience.com/
1995
ABUNDANCE OF AN ENDOGENOUS RETROVIRAL ENVELOPE PROTEIN IN PLACENTAL TROPHOBLASTS SUGGESTS A BIOLOGICAL FUNCTION
VENABLES, P. J. W., BROOKES, S. M., GRIFFITHS, D., WEISS, R. A., & BOYD, M. T. (1995). ABUNDANCE OF AN ENDOGENOUS RETROVIRAL ENVELOPE PROTEIN IN PLACENTAL TROPHOBLASTS SUGGESTS A BIOLOGICAL FUNCTION. VIROLOGY, 211(2), 589-592. doi:10.1006/viro.1995.1442
1994
CD26 ANTIGEN AND HIV FUSION
PATIENCE, C., MCKNIGHT, A., CLAPHAM, P. R., BOYD, M. T., WEISS, R. A., & SCHULZ, T. F. (1994). CD26 ANTIGEN AND HIV FUSION. SCIENCE, 264(5162), 1159-1160. doi:10.1126/science.7909960
CD26 antigen and HIV fusion?
Broder, C. C., Nussbaum, O., Gutheil, W. G., Bachovchin, W. W., & Berger, E. A. (1994). CD26 antigen and HIV fusion?. Science (New York, N.Y.), 264(5162), 1156-1159. doi:10.1126/science.7909959
In vitro assessment of compounds for anti-HIV activity.
Patience, C., Moore, J., & Boyd, M. (1994). In vitro assessment of compounds for anti-HIV activity.. Molecular biotechnology, 1(1), 49-58. doi:10.1007/bf02821510
EVALUATION OF HUMAN ENDOGENOUS RETROVIRUS EXPRESSION IN AML
FOLEY, B., BOYD, M., & BRODSKY, I. (1994). EVALUATION OF HUMAN ENDOGENOUS RETROVIRUS EXPRESSION IN AML. In BLOOD Vol. 84 (pp. A483). Retrieved from https://www.webofscience.com/
1993
A SINGLE AMINO-ACID SUBSTITUTION IN THE V1 LOOP OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP120 ALTERS CELLULAR TROPISM
BOYD, M. T., SIMPSON, G. R., CANN, A. J., JOHNSON, M. A., & WEISS, R. A. (1993). A SINGLE AMINO-ACID SUBSTITUTION IN THE V1 LOOP OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GP120 ALTERS CELLULAR TROPISM. JOURNAL OF VIROLOGY, 67(6), 3649-3652. doi:10.1128/JVI.67.6.3649-3652.1993
THE HUMAN ENDOGENOUS RETROVIRUS ERV-3 IS UP-REGULATED IN DIFFERENTIATING PLACENTAL TROPHOBLAST CELLS
BOYD, M. T., BAX, C. M. R., BAX, B. E., BLOXAM, D. L., & WEISS, R. A. (1993). THE HUMAN ENDOGENOUS RETROVIRUS ERV-3 IS UP-REGULATED IN DIFFERENTIATING PLACENTAL TROPHOBLAST CELLS. VIROLOGY, 196(2), 905-909. doi:10.1006/viro.1993.1556
1992
THE REGION OF THE ENVELOPE GENE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RESPONSIBLE FOR DETERMINATION OF CELL TROPISM
CANN, A. J., CHURCHER, M. J., BOYD, M., OBRIEN, W., ZHAO, J. Q., ZACK, J., & CHEN, I. S. Y. (1992). THE REGION OF THE ENVELOPE GENE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 RESPONSIBLE FOR DETERMINATION OF CELL TROPISM. JOURNAL OF VIROLOGY, 66(1), 305-309. doi:10.1128/JVI.66.1.305-309.1992
1991
ANTISENSE RNA TO TREAT HIV INFECTIONS
BOYD, M. T., & SCHULZ, T. F. (1991). ANTISENSE RNA TO TREAT HIV INFECTIONS. AIDS, 5(2), 225-226. doi:10.1097/00002030-199102000-00016
1989
DETECTION OF RETROVIRUS IN PATIENTS WITH MYELOPROLIFERATIVE DISEASE
BOYD, M. T., MACLEAN, N., & OSCIER, D. G. (1989). DETECTION OF RETROVIRUS IN PATIENTS WITH MYELOPROLIFERATIVE DISEASE. LANCET, 1(8642), 814-817. doi:10.1016/S0140-6736(89)92273-3